

Table 1. List of antibodies used in this study

No.	Marker	Clone	Source	Dilution	Staining pattern
1	ER	SP1	VENTANA	Prediluted	Nuclear
2	PgR	1E2	VENTANA	Prediluted	Nuclear
3	HER2	4B5	VENTANA	Prediluted	Membranous
4	P63	4A4	DAKO	1:50	Nuclear
5	E-cadherin	36	BD Transduction Lab.	1:2000	Membranous
6	CK 5/6	D5/16 B4	DAKO	1:25	Cytoplasmic
7	CK 14	LL002	Novocastra	1:20	Cytoplasmic
8	AR	AR441	DAKO	1:50	Nuclear
9	GCDFP-15	23A3	Novocastra	1:40	Cytoplasmic

CK: Cytokeratin ER: Estrogen receptor. PgR: Progesterone receptor.

AR: Androgen receptor. GCDFP-15: Gross cystic disease fluid protein-15.

Table 2. Clinicopathologic findings in patients with dimorphic IC and non-dimorphic IC

	Dimorphic IC (40 cases)	Non-dimorphic IC (660 cases)	<i>P</i> value*
Mean age	55.4 (40 to 77)	58.1 (27 to 93)	.2381
Mean tumor size (cm)	1.4 (0.4 to 3)	1.6 (0.1 to 7.2)	.0586
Histological grading	I	26 (65.0%)	<.001*
	II	13 (32.5%)	
	III	1 (2.5%)	
Status of nodal metastasis	13 of 40 (32.5%)	237 of 633 (35.9%)	.5305
Stage	I	24 (60.0%)	.4545
	II	11 (27.5%)	
	III	5 (12.5%)	
	IV	0 (0%)	
5-year follow up data available cases	29 of 40	465 of 660	
Recurrence	1 (3.5%)	50 (10.8%)	.2461**
Local recurrence	1 (3.5%)	4 (0.9%)	
Distant metastasis	0 (0%)	46 (9.9%)	
Died of disease	0 (0%)	23 (4.3%)	.2804**
HR+/HER2-	37 (92.5%)	474 (71.8%)	.0042*
HR+/HER2+	1 (2.5%)	40 (6.1%)	.5589
HR-/HER2-	0 (0%)	98 (14.9%)	.0086*
HR-/HER2+	2 (5.0%)	48 (7.2%)	.8213

IC: Invasive carcinoma HR: Hormone receptor * $P < 0.05$ **Log-rank test

Table 3. Clinicopathologic findings in patients with dimorphic DCIS and non-dimorphic DCIS

	Dimorphic DCIS (10 cases)	Non-dimorphic DCIS (124 cases)	<i>P</i> value*
Mean age	53 (41 to 77)	58.2 (27 to 95)	.2819
Mean tumor size (cm)	1.9 (0.5 to 6)	1.4 (0.1 to 10.5)	.3305
Histology	DCIS 9 (90.0%)	DCIS 99 (79.8%)	.9068
	Solid papillary 1 (10.0%)	Solid papillary 14 (11.3%)	
		Encapsulated 8 (6.5%)	
		DCIS in sclerosing adenosis 2 (1.6%)	
		DCIS in fibroadenoma 1(0.8%)	
Grading	Low	5 (50.0%)	.8286
	Intermediate	3 (30.0%)	
	High	2 (20.0%)	
Status of nodal metastasis	0 of 10 (0%)	1 of 108 (0.9%)	.7599
Follow up data available cases	9 of 10	114 of 124	
Recurrence	0 (0%)	2 (1.8%)	.6905
Local recurrence	0 (0%)	1 (0.9%)	
Distant metastasis	0 (0%)	1 (0.9%)	
Die of disease	0 (0%)	0 (0%)	NA
HR+	10 (100.0%)	99 (79.8%)	.1154

DCIS: Ductal carcinoma in situ HR: Hormone receptor NA: Not assessed * $P < 0.05$ **Log-rank test

Table 4. The staining pattern of dimorphic breast carcinoma

	Markers	Dimorphic cells	Adjacent malignant columnar epithelial cells	<i>P</i> value*
Dimorphic IC	P63	1 (2.5%)	0 (0%)	.3143
	E-cadherin	39 (97.5%)	39 (97.5%)	NA
	CK 5/6	0 (0%)	0 (0%)	NA
	CK 14	0 (0%)	0 (0%)	NA
	ER	37 (92.5%)	37 (92.5%)	NA
	AR	35 (87.5%)	35 (87.5%)	NA
	GCDFP-15	34 (85.0%)	34 (85.0%)	NA
Dimorphic DCIS	P63	0 (0%)	0 (0%)	NA
	E-cadherin	10 (100.0%)	10 (100.0%)	NA
	CK 5/6	0 (0%)	0 (0%)	NA
	CK 14	0 (0%)	0 (0%)	NA
	ER	10 (100.0%)	10 (100.0%)	NA
	AR	10 (100.0%)	10 (100.0%)	NA
	GCDFP-15	8 (80.0%)	8 (80.0%)	NA

CK: Cytokeratin ER: Estrogen receptor. AR: Androgen receptor. GCDFP-15: Gross cystic disease fluid protein-15.

NA: Not assessed * $P < 0.05$